Development of an Aerobic Glycolysis Index for Predicting the Sorafenib Sensitivity and Prognosis of Hepatocellular Carcinoma

oleh: Yu Pan, Yu Pan, Yu Pan, Yu Pan, Yu Pan, Yu Pan, Geng-yuan Hu, Geng-yuan Hu, Geng-yuan Hu, Shi Jiang, Shi Jiang, Shi Jiang, Shi Jiang, Shi Jiang, Shi Jiang, Shun-jie Xia, Shun-jie Xia, Shun-jie Xia, Shun-jie Xia, Shun-jie Xia, Shun-jie Xia, Hendi Maher, Hendi Maher, Hendi Maher, Hendi Maher, Hendi Maher, Hendi Maher, Zhong-jie Lin, Zhong-jie Lin, Zhong-jie Lin, Zhong-jie Lin, Zhong-jie Lin, Zhong-jie Lin, Qi-jiang Mao, Qi-jiang Mao, Qi-jiang Mao, Qi-jiang Mao, Qi-jiang Mao, Qi-jiang Mao, Jie Zhao, Jie Zhao, Jie Zhao, Jie Zhao, Jie Zhao, Liu-xin Cai, Liu-xin Cai, Liu-xin Cai, Liu-xin Cai, Liu-xin Cai, Ying-hua Xu, Jun-jie Xu, Jun-jie Xu, Jun-jie Xu, Jun-jie Xu, Jun-jie Xu, Xiu-jun Cai, Xiu-jun Cai, Xiu-jun Cai, Xiu-jun Cai, Xiu-jun Cai

Format: Article
Diterbitkan: Frontiers Media S.A. 2021-05-01

Deskripsi

Hepatocellular carcinoma (HCC) is a deadly tumor with high heterogeneity. Aerobic glycolysis is a common indicator of tumor growth and plays a key role in tumorigenesis. Heterogeneity in distinct metabolic pathways can be used to stratify HCC into clinically relevant subgroups, but these have not yet been well-established. In this study, we constructed a model called aerobic glycolysis index (AGI) as a marker of aerobic glycolysis using genomic data of hepatocellular carcinoma from The Cancer Genome Atlas (TCGA) project. Our results showed that this parameter inferred enhanced aerobic glycolysis activity in tumor tissues. Furthermore, high AGI is associated with poor tumor differentiation and advanced stages and could predict poor prognosis including reduced overall survival and disease-free survival. More importantly, the AGI could accurately predict tumor sensitivity to Sorafenib therapy. Therefore, the AGI may be a promising biomarker that can accurately stratify patients and improve their treatment efficacy.